Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man

Lancet

Volumn 363, Issue 9420, 2004, Pages 1509-1513

  MacLennan, Calman ^a,b,j   Dunn, Glynis ^c   Huissoon, Aarnoud P ^b   Kumararatne, Dinakantha S ^d   Martin, Javier ^c   O'Leary, Paula ^e   Thompson, Ronald A ^b   Osman, Husam ^b   Wood, Philip ^f   Minor, Philip ^c   Wood, David J ^g   Pillay, Deenan ^b,h,i  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE CORK   (Ireland)

^f LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

^j UNIVERSITY OF MALAWI   (Malawi)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DISOXARIL; IMMUNOGLOBULIN; LEUCINE; METHIONINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; PIRODAVIR; PLECONARIL; RIBAVIRIN; SCH 48973; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; BREAST MILK; CASE REPORT; DRUG ACTIVITY; DRUG BINDING; DRUG SENSITIVITY; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS ISOLATION; VIRUS TITRATION; VIRUS VIRULENCE;

EID: 2342481766     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16150-3     Document Type: Article

References (38)

1. MacCallum FO. Hypogammaglobulinaemia in the United Kingdom: the role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (GB). 310:1971;72-85
2. Halsey NA, Pinto J, Espinosa-Rosales F, et al. for the Polio Project Team. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004; 82: 3-8.
3. Abo W, Chiba S, Yamanaka T, Nakao T, Hara M, Tagaya I. Paralytic poliomyelitis in a child with agammaglobulinaemia. Eur J Pediatr. 132:1979;11-16
4. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 36:1998;2893-2899
5. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evolution of poliovirus type I during 5·5 years of prolonged enteral replication in an immunodeficient patient. Virology. 265:1999;178-184
6. Misbah SA, Lawrence PA, Kurtz JB, Chapel HM. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgrad Med J. 67:1991;301-303
7. Dowdle WR, Birmingham ME. The biological principles of poliovirus eradications. J Infect Dis. 175:(suppl 1):1997;286-292
8. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Geneva: World Health Organization, 1988. Available at http://www. polioeradication.org/vaccines/polioeradication/all/background/strategies.asp (accessed March, 2004).
9. Sabin AB. Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 151:1985;420-436
10. Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 175:(suppl 1):1997;176-182
11. Schonberger LB, McGowan JE, Gregg MB. Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epidemiol. 104:1976;202-211
12. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine (IPV) followed by oral poliovirus vaccine. MMWR Morb Mortal Wkly Rep. 46:1997;1-25
13. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 6:2000;1375-1379
14. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine. 12:1994;503-507
15. Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous-system Echovirus infections in patients with agammaglobulinemia. N Engl J Med. 296:1977;1485-1489
16. Wyatt HV. Poliomyelitis in hypogammaglobulinaemics. J Infect Dis. 128:1973;802-805
17. Rosen FS, Cooper MD, Wedgwood RJP. The primary immunodeficiencies. N Engl J Med. 333:1995;431-440
18. WHO. Requirements for poliomyelitis (oral). WHO Tech Rep Ser. 904:1999;31-93
19. Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. Molecular epidemiology of polioviruses. Semin Virol. 6:1995;401-414
20. WHO. Manual for the virological investigation of polio. 1997;World Health Organisation, Geneva
21. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 43:1999;2109-2115
22. Martin J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patients during the entire 637-day period of virus excretion. J Virol. 74:2000;3001-3010
23. Zeichhardt H, Otto MJ, McKinlay MA, Willingmann P, Habermehl KO. Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology. 160:1987;281-285
24. Andries K, Dewindt B, Snoeks J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 36:1992;100-107
25. Lentz KN, Smith AD, Geisler SC, et al. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH4893: comparison of the structural and biological properties of three poliovirus serotypes. Structure. 5:1997;961-978
26. Grant RA, Hiremath CN, Filman DJ, Syed R, Andries K, Hogle JM. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol. 4:1994;784-797
27. Technical Consultative Group to the World Health Organization on Global Eradication of Poliomyelitis. Endgame' issues for the global polio eradication initiative. Clin Infect Dis. 34:2002;72-77
28. Hammon WM, Coriell LL, Wehrle PF, Stokes J. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. J Am Med Soc. 151:1953;1272-1285
29. Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: Excretion of attenuated polio viruses is prolonged. J Clin Immunol. 8:1988;89-94
30. Jatsyk GV, Kuvaeva IB, Gribakin SG. Immunological protection of the neonatal gastrointestinal tract: the importance of breast feeding. Acta Paediatr Scand. 74:1985;246-249
31. Fitzsimmons SP, Evans MK, Pearce CL, Sheridan MJ, Wientzen R, Cole MF. Immunoglobulin A subclasses in infants' saliva and in saliva and milk from their mothers. J Pediatr. 124:1994;566-573
32. Yoneyama T, Hagiwara A, Hara M, Shimojo H. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect Immun. 37:1982;46-53
33. Sabin AB, Fieldsteel AH. Antipoliomyelitic activity of human and bovine colostrum and milk. Paediatrics. 29:1962;105-115
34. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 32:2001;228-235
35. Schmugge M, Lauener R, Bossart W, Seger RA, Gungor T. Chronic enteroviral meningo-encephalitis in X-linked agammaglobulinaemia: favourable response to anti-enteroviral treatment. Eur J Pediatr. 158:1999;1010-1011
36. Nowak-Wegrzyn A, Phipatanakul W, Winkelstein JA, Forman MS, Lederman HM. Successful treatment of enterovirus infection with the use of pleconaril in 2 infants with severe combined immunodeficiency. Clin Infect Dis. 32:2001;13-14
37. Mosser AG, Sgro JY, Rueckert RR. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol. 68:1994;8193-8201
38. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA. 100:2003;7289-7294